Taiwan’s approach to evaluating the efficacy of COVID-19 vaccine candidates has not been used by any other country as a basis for granting emergency use authorization (EUA), Minister of Health and Welfare Chen Shih-chung (陳時中) said on Friday.
During a legislative hearing, Taiwan People’s Party Legislator Ann Kao (高虹安) questioned Chen about review standards for issuing EUAs for domestic COVID-19 vaccines, which the Food and Drug Administration (FDA) published on Thursday.
While Taiwan’s domestically developed vaccine candidates have completed phase 1 and 2 clinical trials, none of them have begun larger phase 3 trials — which are typically the standard for determining efficacy. FDA guidelines allow EUAs to be issued without phase 3 trials, by instead analyzing phase 2 results through immunobridging, which uses the immune response measured in clinical trial participants to infer the overall level of protection a vaccine would provide.
Photo courtesy of the Kaohsiung City Government Department of Health via CNA
Critics say that this approach, which is based on the potency levels of neutralizing antibodies found in clinical trial participants, cannot be used to accurately determine a vaccine’s efficacy.
Kao asked Chen whether Taiwan would be the first country to grant an EUA using immunobridging as a substitute for efficacy data obtained in phase 3 clinical trials.
Initially, Chen said that he could not speak to the approaches being adopted by regulators in other countries, adding that immunobridging has been a topic of discussion in the WHO.
When pressed, Chen said that “there are currently no approvals of this type.”
“If that is the case, then this is genuinely frightening,” Kao said. “Taiwan has purchased 10 million [local] vaccines, enough to give to 5 million people.”
“If the efficacy of the domestic vaccines does not meet expectations, then these people are like the emperor with no clothes — completely without protection,” she said.
Russia and China have approved COVID-19 vaccines for use before they entered phase 3 trials or before efficacy data from those trials had been published, but Taiwan would be the first country to grant an EUA using the immunobridging approach, Chen said.
Debate on the FDA’s standards has grown, following Medigen Vaccine Biologics’ announcement on Thursday that it would soon apply for an EUA, after becoming the first local vaccine maker to “unblind” results of its phase 2 clinical trials.
The FDA’s review would compare the neutralizing antibody potency levels of Medigen trial participants with those from a control group of 200 recipients of the AstraZeneca vaccine in Taiwan, Chen said.
As data from the AstraZeneca group is pending, the EUA review would likely begin later this month, Chen said, adding that there would be no pressure on the FDA and no deadline for when it should be completed.
In a follow-up question, Kao said that the US Food and Drug Administration had publicly broadcast its EUA review meetings for the Moderna COVID-19 vaccine, and asked Chen if Taiwan would be willing to do the same.
Chen said that he would respect whatever decision the vaccine review committee made on the matter, but added that there are no plans to broadcast the proceedings.
If Medigen’s vaccine is granted an EUA and if plans to use immunobridging, with phase 3 trials to be conducted later, gain traction internationally, the vaccine would have a chance of being approved by the WHO, Chen said.
Even without international recognition, Taiwanese would not be prohibited from entering other countries based on what vaccine they receive, although quarantine procedures might differ, he added.
Twenty-four Republican members of the US House of Representatives yesterday introduced a concurrent resolution calling on the US government to abolish the “one China” policy and restore formal diplomatic relations with Taiwan. Led by US representatives Tom Tiffany and Scott Perry, the resolution calls for not only re-establishing formal relations, but also urges the US Trade Representative to negotiate a free-trade agreement (FTA) with Taiwan and for US officials to advocate for Taiwan’s full membership in the UN and other international organizations. In a news release announcing the resolution, Tiffany, who represents a Wisconsin district, called the “one China” policy “outdated, counterproductive
ON PAROLE: The 73-year-old suspect has a criminal record of rape committed when he was serving in the military, as well as robbery and theft, police said The Kaohsiung District Court yesterday approved the detention of a 73-year-old man for allegedly murdering three women. The suspect, surnamed Chang (張), was arrested on Wednesday evening in connection with the death of a 71-year-old woman surnamed Chao (趙). The Kaohsiung City Police Department yesterday also unveiled the identities of two other possible victims in the serial killing case, a 75-year-old woman surnamed Huang (黃), the suspect’s sister-in-law, and a 75-year-old woman surnamed Chang (張), who is not related to the suspect. The case came to light when Chao disappeared after taking the suspect back to his residence on Sunday. Police, upon reviewing CCTV
Johanne Liou (劉喬安), a Taiwanese woman who shot to unwanted fame during the Sunflower movement protests in 2014, was arrested in Boston last month amid US President Donald Trump’s crackdown on illegal immigrants, the Criminal Investigation Bureau (CIB) said yesterday. The arrest of Liou was first made public on the official Web site of US Immigration and Customs Enforcement (ICE) on Tuesday. ICE said Liou was apprehended for overstaying her visa. The Boston Field Office’s Enforcement and Removal Operations (ERO) had arrested Liou, a “fugitive, criminal alien wanted for embezzlement, fraud and drug crimes in Taiwan,” ICE said. Liou was taken into custody
TRUMP ERA: The change has sparked speculation on whether it was related to the new US president’s plan to dismiss more than 1,000 Joe Biden-era appointees The US government has declined to comment on a post that indicated the departure of Laura Rosenberger as chair of the American Institute in Taiwan (AIT). Neither the US Department of State nor the AIT has responded to the Central News Agency’s questions on the matter, after Rosenberger was listed as a former chair on the AIT’s official Web site, with her tenure marked as 2023 to this year. US officials have said previously that they usually do not comment on personnel changes within the government. Rosenberger was appointed head of the AIT in 2023, during the administration of former US president Joe